Ervebo, an Ebola vaccine from Merck, received marketing approval from the European Commission today (November 11), marking the first such vaccine to reach the world’s markets.

“Finding a vaccine as soon as possible against this terrible virus has been a priority for the international community ever since Ebola hit West Africa five years ago,” Vytenis Andriukaitis, the European Commission official in charge of health and food safety, says in a statement. “Today’s decision is therefore a major step forward in saving lives in Africa and beyond.”

Merck first took over the development of the vaccine after the Ebola outbreak in West Africa started in 2014. The immunization was initially designed by researchers at Canada’s National Microbiology Laboratory and then licensed to Iowa-based biotech company NewLink Genetics. Starting in 2015, Merck conducted a highly successful clinical trial in Guinea. More than 250,000 doses of Ervebo...

See “Uganda Launching New Experimental Ebola Vaccine Trial

The US Food and Drug Administration is currently reviewing Merck’s application, with a decision expected before March 2020, STAT reports.

Jef Akst is managing editor of The Scientist. Email her at jakst@the-scientist.com

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?